Detailed deletion mapping of chromosome 6q sequences in invasive ovarian tumors have implicated several broad regions involving 6q14 ± 16, 6q21 ± 23, 6q25 ± 26, and the telomeric portion in band 6q27 as regions of frequent loss in this malignancy. In order to de®ne regions of loss involved in the development of ovarian cancer, we used 23 polymorphic markers on 6q to examine allelic loss in 25 high-grade, late stage ovarian tumors. Four nonoverlapping deletion regions were observed: (1) at 6q21 ± 22.3 (D6S301-D6S292); (2) within a 1 cM region at 23.2 ± 23.3 between markers D6S978-D6S1637 (at D6S311); (3) at 6q26 (between markers D6S411-D6S1277) and (4) at 6q27 with the markers D6S297 and D6S193. The highest region of loss was observed with marker D6S311 (lost in 17 of 19 informative cases, 89%) in 6q23.3, followed by D6S977 and D6S1637 (71 and 55%, respectively). The average fractional allele loss in the high-grade tumors was around 35%. Previous reports have shown 6q27 as the region of most frequent loss in invasive ovarian cancer. However, our results indicate a novel region in 6q23.3 (spanning less than 500 Kb distance between the markers) with the highest loss, implicating this region of chromosome 6q to harbor a putative tumor suppressor gene involved in the development of invasive epithelial ovarian cancer.
Ovarian cancer is one of the leading causes of cancer deaths unique to women (Landis et al., 1998) . The incidence and mortality of ovarian cancer has not changed in the past decade (Henderson et al., 1991) . The reason for this high mortality rate is attributed to late diagnosis, usually occurring during the late stages of the disease (Cannistra, 1993) . Despite the recent progress in the identi®cation of cancer-related genes, the underlying genetic pathways of ovarian carcinogenesis are not well known. The molecular studies of the late stage invasive tumors could provide information that can be used for a more detailed diagnosis of these tumors and lead to a better understanding of the pathogenesis of ovarian carcinomas.
In common with other types of tumors, inactivation of tumor suppressor genes and activation of oncogenes are most likely involved in the multi-step process of ovarian carcinogenesis. Loss of heterozygosity (LOH) studies have delineated chromosomal regions on 1p, 3p, 5q, 6q, 7q, 8p, 9p, 13q and 17p (Clibey et al., 1993; Dodson et al., 1993; Jiang et al., 1996; Foulkes et al., 1993; Saito et al., 1992) that may be involved in the development of this cancer. However, no ovarian tumor suppressor genes have yet been identi®ed. In recent years the long arm of chromosome 6 has been extensively studied for LOH in epithelial ovarian cancer. Frequent allelic deletions have been reported in 6q21 ± 23.3 in benign and endometrioid tumors (Orphanos et al., 1995) , and more recently 6q27 has been the target of intense investigations. Hauptchein et al. (1998) Saito et al. (1996) and Tibiletti et al. (1998) have shown that markers from this region have a high frequency of allele loss in invasive epithelial ovarian carcinomas. Colitti et al. (1998) recently reported a novel region in 6q25.1 ± 25.2 that showed 43 ± 44% loss de®ned by markers D6S448 and D6S473, respectively, in high-grade invasive epithelial ovarian carcinomas.
Molecular evidence of allelic losses of 6q has been described in several dierent types of cancers. These include cancers of the breast (Sheng et al., 1996; Chappell et al., 1997) , gastric cancer (Quimado et al., 1995) , lymphoblastoid leukemia, B-cell lymphoma (Guan et al., 1996) , melanoma (Walker et al., 1994) , prostate cancer (Cooney et al., 1996) , and more recently in malignant mesothelioma (Bell et al., 1997) . Additional evidence for the presence of tumor suppressor genes on the long arm of chromosome 6 has come from studies involving microcell-mediated chromosome transfer (MMCT). Sandhu et al. (1994) have shown that the introduction of a normal human chromosome 6 or 6q by microcell-mediated chromosome transfer (MMCT) can suppress the immortal phenotype of SV40 transformed human ®broblasts. LOH analysis of several independent SV40 transformants subsequently mapped the aected locus (SEN6) to the distal arm of 6q at 6q26 ± 27 (Banga et al., 1997) . Other studies involving MMCT of fragments of 6q have de®ned regions that contain tumor suppressor genes (TSG) including 6q23.3 ± 6q25 in breast tumors (Theile et al., 1996) and 6q14 ± 21 in ovarian tumor cells (Sandhu et al., 1996) . A growth suppressor gene was mapped to band 6q21 by deletion analysis after transfer of a normal human chromosome 6 into a BK virus-transformed mouse cell line by Morrelli et al. 1997) . There are several candidate tumor suppressor genes on 6q including cyclin C at 6q23, hLOT-1 in 6q24 ± 25 (Abdollahi et al., 1997) , and Mn-SOD at 6q25.3. In order to identify additional regions of loss on 6q, we used a set of closely spaced markers in 6q23.2, 6q23.3 and 6q26 to look for LOH in invasive epithelial ovarian cancer. Included in the study are the markers that showed the highest loss in 6q27 by other investigators. This work has delineated a novel region in 6q23.3 of less than 500 Kb found to be deleted in 91% of the late-stage ovarian tumors.
We examined loss of heterozygosity (LOH) using 23 polymorphic microsatellite markers on the long arm of chromosome 6 in and 25 high-grade (3 and 4) ovarian tumors. With the exception of tumor #25 (stage IIB), the 24 other tumors were high stage (IIIC to IV) tumors; 23 of the 25 tumors showing LOH on 6q were serous adenocarcinomas and two endometrioid adenocarcinomas (tumors 15 and 20). The map positions and the genetic distance between the markers are based on the LDB database (Genetic location database at the University of Southampton, UK). All the tumors analysed had losses involving three or more markers. There were no tumors that showed retention of all the markers tested in this study. The reason for this might be that all the tumors analysed had a high proportion of tumor cells (90 ± 95%) by microscopic examination and they were all stage III or IV (with the exception of tumor #25).
Seven of 23 markers chosen for analysis map to 6q22.3 ± 23.3, a region previously was shown to have a high frequency of allele loss in several other tumor types (Sheng et al., 1996; Chappell et al., 1997; Quimado et al., 1995; Guan et al., 1996; Walker et al., 1994; Jiang et al., 1996; Cooney et al., 1996) . Markers D6S292 and D6S311, which were included in this study, de®ned the minimal region required to suppress tumorigenicity in a breast cancer cell line using microcell-mediated chromosome transfer (Theile et al., 1996) . Seven of the 23 markers mapped to 6q27, a region that has been implicated to contain a tumor suppressor gene for high-grade invasive ovarian tumors of epithelial origin (Cooke et al., 1996) . Markers D6S1693 and D6S281 at 6q27 represent the telomeric end of 6q27. Of the 25 high-grade tumors analysed, 16 were grade III tumors and 9 were grade IV. Table 1 summarizes the results of the samples that had LOH of at least one or more markers for all the ovarian tumor samples. Allele loss of the markers tested ranged from 24% with D6S449 to 89% with D6S311. The percentage of tumors with LOH and the genetic distances between the markers used in this analysis is shown in Table 2 . Figure 1 shows some representative microsatellite analyses of matched normal-tumor pairs with some of the markers. It also shows how a minimal region of loss was de®ned in a particular region (with retention of markers on either side of loss). Figure 2 is a schematic representation showing the frequency of allele loss of the tested microsatellites in the tumor samples. This ®gure clearly illustrates that there are at least four regions of allele loss on 6q in invasive epithelial ovarian cancer (IOECs).
All the 25 high-grade samples analysed showed loss indicative of interstitial deletions as evidenced by allelic loss at some loci and retention at others ( Table 2 ). The samples showing interstitial deletions de®ned four regions of loss on 6q.
Losses in region #1 can be de®ned using three markers that map to 6q21 ± 22.3. A minimal deleted region (MDR) can be de®ned by heterozygous deletion of D6S301 and D6S292 at 6q21 ± 22.3 in tumors #2, 5, 7, 16, 24 and 25 while the¯anking markers D6S449 and D6S310 retained heterozygosity. The boundaries of any speci®c region are de®ned by the presence or retention of markers (when they are informative) on either side, with loss of heterozygosity of markers within this boundary.
A similar kind of analysis can be used to de®ne region 2. The six markers in 6q23.2 ± 23.3 de®ne an MDR in tumors #7, 8, 9, 10, 11, 16, 17, 19, 23 and 25 . The marker showing the highest frequency of LOH in this region, D6S311 (89%), is¯anked by the more distal marker D6S977 which showed 71% LOH and proximal marker D6S978 with 38% LOH. According to the LDB database, the genetic distance between D6S311 and D6S977 is less than 500 Kb. Altogether these tumors and tumors 3, 4, 5, 6, 12, 13, 14, 20, 21 and 22 had lost one or the other marker de®ning this region. Only one tumor (tumor 15) had retention of both D6S311 and D6S977 while tumor #2 and 18 were uninformative for both the markers and tumor #24 had retention of D6S311 and uninformative at the D6S977 locus. Taken together these two markers are lost in 21 of 23 (91%) informative tumors in this region. Cooke et al. (1996) analysed 56 malignant ovarian tumors with 19 markers on 6q including some of the Tumors were collected from patients undergoing surgery for ovarian cancer at the Mayo Clinic in Rochester, Minnesota. Fresh tumor samples were snap frozen at 7708C until processed for DNA extraction. Tumor specimens were cryostat sectioned before DNA extraction. The sections were reviewed by a pathologist (Dr G Keeney) to assess the tumor content in each section and for determination of histopathological subtype and grade. Only sections containing 490% tumor cells were used for DNA extraction. For constitutional DNA, blood samples were used from each patient Novel region of 6q loss in ovarian cancer V Shridhar et al markers used in this study. In their sample set, the per cent allele loss with D6S311 was below the 35% threshold that distinguishes random from nonrandom chromosomal loss seen in high-grade tumors Dodson et al., 1993) . The reason for the dierences in the frequency of allele loss between these two groups with this marker is not clear. It may be attributed to geographical or population dierences and probably to the presence of a high proportion of normal cells in their samples. In addition, we analysed closely spaced markers in this region and the marker less than 500 Kb distal to D6S311, D6S977 also showed a high frequency of loss (71%). This frequency of loss is almost as high as what was observed for the 6q27 marker D6S193 in the study by Cooke et al. (1996) . Most of the other reports Foulkes et al., 1993; Orphanos et al., 1995; Rodabaugh et al., 1995) on the ®ne scale deletion mapping of 6q markers have not included such closely spaced markers in 6q23.2 ± 23.3 as this study has. Also of importance is the observation that chromosomal segments containing markers D6S311 and D6S292 were shown to suppress tumorigenicity after microcell-mediated chromosome transfer into a breast cancer cell line (Thiele et al., 1996) . Based on the information from the genetic location database (lbd) (Collins et al., 1996) , the sex averaged recombination distance between markers D6S292 and D6S977 is estimated to be about 18 cM. In their analysis of 46 breast cancer tumors, Thiele et al. (1996) reported a higher frequency of LOH at D6S311 (35%) compared to D6S292 (15%) and 18% LOH with the marker D6S310. The suppression of neoplastic phenotype observed in the microcell hybrid was attributed to the action of a tumor suppressor gene in the vicinity of D6S311. With the availability of closely spaced markers in our samples, we have de®ned a very small region of 5500 Kb with the highest frequency of loss in 6q23.3 between markers D6S311 and D6S977 as a novel region in ovarian cancer that may harbor a tumor suppressor gene. According to the Unigene database, homo sapiens metabotropic glutamate receptor 1 alpha (mGluR1alpha) mRNA is mapped to this region. So far there are no reports of the involvement of this gene in ovarian carcinogenesis. Fifty-®ve per cent of tumors had LOH at both the D6S960 and ESR locus while 35% of the tumors showed LOH of the IGF2R locus. The reported allele loss at the ESR locus in ovarian tumors range between 15 ± 17% (Colitti et al., 1998; Leary et al., 1993) and as high as 56% (Cooke et al., 1996) to 64% (Lee et al., 1990) . The recombination distance between D6S977 at 6q23.3 to ESR at 6q24.2 is about 6 cM. Since the average fractional allele loss in our samples is about 35%, the loss at the ESR locus may not be signi®cant.
A more limited number of tumors serve to de®ne a third region at 6q26 (Tumors 2, 4, 9, 10, 16, 17, 20, 21, 22, 23, 24 and 25) compared to region #2. This region is represented by marker D6S1008 and shows the second highest frequency of LOH in these tumors (82%)¯anked proximally by D6S411 with 33% LOH and distally by D6S1277 with 53% LOH. The candidate gene mapped in this interval is Mn-SOD2. Mn-SOD2 has been shown to inhibit tumorigenesis when over-expressed in melanoma cells (Church et al., 1993) . Although Cliby et al. (1993) and Foulkes et al. (1993) have reported high frequencies of LOH of this locus in ovarian tumors, there is no direct evidence that SOD2 is the tumor suppressor involved in ovarian carcinogenesis.
Common fragile sites are chromosomal regions present in most or all individuals and are prone to gaps and breaks. There are several fragile sites mapped to 6q. While the fragile site FRA6D at 6q13 is induced with BrdU, other fragile sites such as FRA6G at 6q15, FRA6F at 6q21, and FRA6E at 6q26 are all induced with aphidicolin. The clinical signi®cance of fragile sites may be the role they play in chromosomal breakage and deletion during cancer development. We have demonstrated that a high percentage of both pancreatic adenocarcinomas (Shridhar et al., 1996) and sporadic RCCs (Shridhar et al., 1997) have breakpoints in FRA3B, one of the most common aphidicolininducible fragile sites in the human genome (Wang et al., 1993) . The LOH data in this study indicates that the region with the second highest heterozygous loss on 6q contains the FRA6E common fragile site.
The fourth region is represented by markers in 6q27 (D6S1585, D6S297, D6S193 and D6S1697). This region has been the focus of intense investigations in ovarian carcinomas (Saito et al., 1997; Cooke et al., 1996) . As evidenced by others, there is a high frequency of loss with markers D6S297 and D6S193 (79% each) in this region rendering additional support for the existence of a tumor suppressor gene or genes in this region. A terminal deletion at or proximal to D6S281 is also evident in some tumors.
Thus the allelic losses in all 26 tumors fall into four regions of deletion. As expected several of the regions de®ned here coincide with peaks in the frequency of LOH at individual loci; for example, D6S301 and D6S292 at region #1, D6S311 at region #2, D6S1008 at region #3 and D6S297 and D6S193 at 6q27. Although we have de®ned four regions of deletions, it is clear that some of the tumors have overlapping deletions 32 CTP (10 mci/ml) and 0.5 units of Taq polymerase (Promega) in a 10 ml reaction volume. The conditions for ampli®cation were: 948C for 2 min, then 30 cycles of 948C for 30 s, 52 ± 578C for 30 s, and 728C for 30 s in a Perkin Elmer-Cetus 9600 Gene-Amp PCR system in a 96 well plate. The PCR products were denatured and run on 6% polyacrylamide sequencing gels containing 8 M urea. The gels were dried and autoradiographed for 16 ± 24 h and scored for LOH. Multiple exposures were used before scoring for LOH. Allelic imbalance indicative of LOH were scored when there was more than 50% loss of intensity of one allele in the tumor sample with respect to the matched allele from normal tissue. The evaluation of the intensity of the signal between the dierent alleles was determined by visual examination by two independent viewers (VS and JS). Autoradiographs of LOH results of selected tumor samples in three distinct regions of 6q. involving multiple regions. Tumor #1 was the only tumor that showed loss at several informative loci tested suggesting the loss of all tested 6q sequences.
In conclusion, we have identi®ed four regions of independent deletions in ovarian cancer, and we have de®ned a novel and very small minimally deleted region in 6q23.3 spanning less than 500 Kb with the highest observed frequency of LOH. Deletions in this region have not been described before in ovarian cancer. The small size of this region will facilitate the construction of a BAC contig followed by the direct cloning of a potential tumor suppressor gene associated with the development of this aggressive tumor.
